Additionally, as for PTCL, data on response to brentuximab vedotin in patients with low or no CD30 expression are also required to determine the optimal role of brentuximab vedotin across CTCL subtypes. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.